Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Ottawa
$27,000.00
Furin-Cleaved Proprotein Convertase Subtilisin/Kexin Type 9 in Atherosclerotic Inflammation
EF 2025-26
Résumé
Cardiovascular disease is a leading cause of death in Canada, primarily due to atherosclerosis from cholesterol buildup. PCSK9, a serine protease, is known for promoting degradation of LDL receptors (LDLRs) that internalize plaque-forming cholesterol from the bloodstream. Beyond their lipid-lowering effects, PCSK9 inhibitor therapies have demonstrated anti-inflammatory properties, revealing PCSK9’s pro-inflammatory role. Within plaques, PCSK9 is expressed in macrophages, endothelial cells, and smooth muscle cells, where it upregulates pro-inflammatory cytokines like interleukin-1B (IL-1B) and IL-6. This inflammation is implicated in plaque destabilization, risking thrombotic myocardial infarction. Furthermore, PCSK9 has distinct subtypes, including its furin-cleaved form (f-PCSK9), whose differences compared to wild-type (WT) PCSK9 (uncleaved form) remain underexplored. Importantly, by blocking the PCSK9-LDLR binding interface, PCSK9 inhibitors also prevent furin cleavage of PCSK9. Notably, their anti-inflammatory effects may be due to preventing f-PCSK9 formation. Yet no studies distinguish the relative contributions of f-PCSK9 and WT to the observed pro-inflammatory effects. Hence, my novel hypothesis: f-PCSK9 induces a stronger pro-inflammatory cytokine response than WT due to preferential uptake in macrophages. Thus, I treat THP-1 macrophages with f-PCSK9 and WT. Thereafter, qRT-PCR demonstrates higher pro-inflammatory cytokine mRNA with f-PCSK9 treatment, consistent with Western blot showing preferential uptake of the f-PCSK9 variant. Such inflammation drives detrimental atherosclerosis despite cholesterol-lowering drugs. As such, my delineation of the functional differences between f-PCSK9 and WT is vital for designing variant-specific, life-saving interventions.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
572544
Name
Sivasathiyanathan Soumiya
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Furin-Cleaved Proprotein Convertase Subtilisin/Kexin Type 9 in Atherosclerotic Inflammation
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Atherosclerosis; Furin; Inflammation; Macrophage; Pcsk9
Abstract
Cardiovascular disease is a leading cause of death in Canada, primarily due to atherosclerosis from cholesterol buildup. PCSK9, a serine protease, is known for promoting degradation of LDL receptors (LDLRs) that internalize plaque-forming cholesterol from the bloodstream. Beyond their lipid-lowering effects, PCSK9 inhibitor therapies have demonstrated anti-inflammatory properties, revealing PCSK9’s pro-inflammatory role. Within plaques, PCSK9 is expressed in macrophages, endothelial cells, and smooth muscle cells, where it upregulates pro-inflammatory cytokines like interleukin-1B (IL-1B) and IL-6. This inflammation is implicated in plaque destabilization, risking thrombotic myocardial infarction. Furthermore, PCSK9 has distinct subtypes, including its furin-cleaved form (f-PCSK9), whose differences compared to wild-type (WT) PCSK9 (uncleaved form) remain underexplored. Importantly, by blocking the PCSK9-LDLR binding interface, PCSK9 inhibitors also prevent furin cleavage of PCSK9. Notably, their anti-inflammatory effects may be due to preventing f-PCSK9 formation. Yet no studies distinguish the relative contributions of f-PCSK9 and WT to the observed pro-inflammatory effects. Hence, my novel hypothesis: f-PCSK9 induces a stronger pro-inflammatory cytokine response than WT due to preferential uptake in macrophages. Thus, I treat THP-1 macrophages with f-PCSK9 and WT. Thereafter, qRT-PCR demonstrates higher pro-inflammatory cytokine mRNA with f-PCSK9 treatment, consistent with Western blot showing preferential uptake of the f-PCSK9 variant. Such inflammation drives detrimental atherosclerosis despite cholesterol-lowering drugs. As such, my delineation of the functional differences between f-PCSK9 and WT is vital for designing variant-specific, life-saving interventions.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sivasathiyanathan, Soumiya
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~